Items without sitelinks
From determinar.ia.br - Determine suas informações
Showing below up to 50 results in range #12,351 to #12,400.
- Assault by exposure to or harmful effects of penicillins (Q100459)
- Assault by exposure to or harmful effects of other drugs acting on muscles (Q100458)
- Assault by exposure to or harmful effects of cephalosporins or other beta-lactam antibiotics (Q100457)
- Assault by exposure to or harmful effects of other antidysrhythmic drugs (Q100456)
- Assault by exposure to or harmful effects of macrolides (Q100455)
- Assault by exposure to or harmful effects of calcium-channel blockers (Q100454)
- Assault by exposure to or harmful effects of other antiprotozoal drugs (Q100453)
- Assault by exposure to or harmful effects of centrally-acting or adrenergic-neuron-blocking agents (Q100452)
- Assault by exposure to or harmful effects of alpha-adrenoreceptor antagonists (Q100451)
- Assault by exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists (Q100450)
- Assault by exposure to or harmful effects of ganglionic blocking drugs (Q100449)
- Assault by exposure to or harmful effects of antimalarials or drugs acting on other blood protozoa (Q100448)
- Assault by exposure to or harmful effects of beta-adrenoreceptor antagonists (Q100447)
- Assault by exposure to or harmful effects of sulfonamides (Q100446)
- Assault by exposure to or harmful effects of antimycobacterial drugs (Q100445)
- Assault by exposure to or harmful effects of other parasympatholytics or spasmolytics (Q100444)
- Assault by exposure to or harmful effects of other hormones or synthetic substitutes (Q100443)
- Assault by exposure to or harmful effects of anticholinesterase agents (Q100442)
- Assault by exposure to or harmful effects of other parasympathomimetics (Q100441)
- Assault by exposure to or harmful effects of other hormone antagonists (Q100440)
- Assault by exposure to or harmful effects of predominantly beta-adrenoreceptor agonists (Q100439)
- Assault by exposure to or harmful effects of anterior pituitary hormones (Q100438)
- Assault by exposure to or harmful effects of unspecified hormone antagonists (Q100437)
- Kyphoscoliotic heart disease (Q100436)
- Assault by exposure to or harmful effects of oral contraceptives (Q100435)
- Acquired displacement of heart (Q100434)
- Assault by exposure to or harmful effects of antithyroid drugs (Q100433)
- Assault by exposure to or harmful effects of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified (Q100432)
- Assault by exposure to or harmful effects of androgens or anabolic congeners (Q100431)
- Benign renovascular hypertension (Q100430)
- Venous collateral circulation, any site (Q100429)
- Autosomal dominant progressive nephropathy with hypertension (Q100428)
- Renal artery stenosis due to fibromuscular hyperplasia (Q100427)
- Arterial hypertension due to renal artery stenosis secondary to vasculitis (Q100426)
- Renal artery stenosis due to congenital abnormality (Q100425)
- Malignant renal hypertension (Q100424)
- Pseudohyperaldosteronism type 1 (Q100423)
- Assault by exposure to or harmful effects of thyroid hormones or substitutes (Q100422)
- Pseudohypoaldosteronism type 2 (Q100421)
- Assault by exposure to or harmful effects of other estrogens or progestogens (Q100420)
- Assault by exposure to or harmful effects of insulin or oral hypoglycaemic drugs (Q100419)
- Pseudohyperaldosteronism type 2 (Q100418)
- Assault by exposure to or harmful effects of glucocorticoids or synthetic analogues (Q100417)
- Malignant renovascular hypertension (Q100416)
- Assault by exposure to or harmful effects of unspecified hormones or synthetic substitutes (Q100415)
- Hypertension due to congenital adrenal hyperplasia (Q100414)
- Hypertension due to aortic arch obstruction (Q100413)
- Disorder of cardiovascular system (Q100412)
- Cardiovascular stenosis (Q100411)
- Dysfunction of papillary muscle (Q100410)
